Hong Kong Regulator Suspends Cloudbreak Pharma Shares Over 'Rigged' IPO Probe
SCMP · 1 SOURCES1 day ago2 MIN
Summary
Hong Kong's Securities and Futures Commission (SFC) has directed the stock exchange to suspend trading of Cloudbreak Pharma, a US-based biotechnology company, amid an investigation into its initial public offering (IPO) last year. The regulator says it has "serious concerns" that the HK$611.88 million (US$78.45 million) IPO may have been rigged to create an artificial impression of demand for the company's shares. Trading was halted at 9am on Thursday, before the market opened.
Key Points
- The SFC ordered suspension of Cloudbreak Pharma shares on September 10, 2026, pending investigation into alleged IPO manipulation
- Cloudbreak raised HK$611.88 million (US$78.45 million) in its IPO in late June 2025 under Chapter 18A rules for pre-revenue biotech companies
- The retail tranche was oversubscribed by 77 times with 29,007 retail investors, while the international tranche attracted only 168 investors subscribing to 89% of its offering
- The share price collapsed 39% on its first trading day and has lost over 90% from its IPO price of HK$10.10, closing at HK$1.19 on Wednesday
- Company founder and CEO Ni Jinsong established Cloudbreak in California in 2015 after approximately 20 years working for Pfizer and Allergan
Why It Matters
This case tests Hong Kong's regulatory resolve in policing IPO irregularities at a time when Chapter 18A rules have made the city one of the world's largest fundraising hubs for biotech companies. The investigation signals that authorities are willing to act decisively to root out artificial demand manipulation, even if it means freezing shares of a company that has been a major fundraising success story since its 2018 introduction .
This case tests Hong Kong's regulatory resolve in policing IPO irregularities at a time when Chapter 18A rules have made the city one of the world's largest fundraising hubs for biotech companies. The investigation signals that authorities are willing to act decisively to root out artificial demand manipulation, even if it means freezing shares of a company that has been a major fundraising success story since its 2018 introduction .